Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This event by the BIA Science and Innovation Advisory Committee (SIAC) will help SMEs involved in discovering new therapies and diagnostics understand how they can benefit from digital tools and innovations to accelerate R&D, reduce the risks, and transform their businesses.

Accelerating Drug Discovery through digital and AI innovations Flyer

Emerging data technologies and AI are already identifying the drivers behind disease and discovering new approaches to diagnose and treat those diseases. Case studies will be presented from organisations that have successfully used AI and digital tools in discovery, covering data generation, manipulation, and application. Further workshops are likely to follow on topics identified by attendees, so please do share your thoughts on how we can support you in this area.

Agenda

09:15   Sign in and networking


09:30   Welcome
             
Justin Bryans, LifeArc


09:35   Data application - example 1
             Dan Jamieson, Biorelate

09:50   Data application - example 2


10:05   Data generation and access
             Rafael Jimenez, Medicines Discovery Catapult


10:20   Data-driven computational approaches for identifying novel therapeutic targets and drug repositioning opportunities
             Namshik Han, Milner Therapeutics Institute, University of Cambridge


10:35   Break


10:50   Live Q&A and panel discussion - chaired by Karen Wilkinson (KTN) and Liliya Serazetdinova (Earlham Institute)
             
Dan Jamieson, Biorelate
             Rafael Jimenez, Medicines Discovery Catapult
             Namshik Han, Milner Institute
             Richard Goodwin, AstraZeneca


11:50   Summary and closing remarks
             
Justin Bryans, LifeArc

 

Click here to register